日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

MON-366 Lonigutamab, a Novel Anti-IGF-1R, Has a Limited Impact on Circulating IGF-1 Levels

MON-366 Lonigutamab 是一种新型抗 IGF-1R 药物,对循环 IGF-1 水平的影响有限。

Ahmed, Hanya; Zhang, Qianni; Donnan, Robert; Alomainy, Akram; Kahaly, George J; Subramanian, Prem S; Nyborg, Andrew; Nguyen, Anh; Grover, Anita; de Jong, Petrus R; Welch, Brett; Archer, Chase; Imm, So Jung; Mpofu, Shephard; Ugradar, Shoaib

Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease

Teprotumumab 用于治疗难治性甲状腺眼病

Men, Clara J; Amarikwa, Linus; Pham, Brandon; Sears, Connie; Clauss, Kevin; Lee, Bradford W; Lee, Wendy W; Pasol, Joshua; Ugradar, Shoaib; Shinder, Roman; Cockerham, Kimberly; Wester, Sara; Douglas, Raymond; Kossler, Andrea L

Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity

Teprotumumab治疗病程较长、疾病活动度较低的甲状腺眼病患者的疗效和安全性

Douglas, Raymond S; Couch, Steven; Wester, Sara T; Fowler, Brian T; Liu, Catherine Y; Subramanian, Prem S; Tang, Rosa; Nguyen, Quang T; Maamari, Robi N; Ugradar, Shoaib; Hsu, Kate; Karon, Michael; Stan, Marius N

Changing the face of thyroid eye disease

改变甲状腺眼病的面貌

Ugradar, Shoaib; Goldberg, Robert A; Douglas, Raymond S

Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison

特普鲁单抗联合安慰剂与静脉注射甲泼尼龙推荐治疗方案在治疗中重度甲状腺眼病引起的眼球突出和复视方面的疗效比较:一项荟萃分析和匹配调整的间接比较研究

Douglas, Raymond S; Dailey, Roger; Subramanian, Prem S; Barbesino, Giuseppe; Ugradar, Shoaib; Batten, Ryan; Qadeer, Rana A; Cameron, Chris

Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach

采用改良德尔菲法就替普罗木单抗在甲状腺眼病治疗中的应用达成专家共识

Douglas, Raymond S; Kossler, Andrea L; Abrams, Jody; Briceño, Cesar A; Gay, David; Harrison, Andrew; Lee, Michael; Nguyen, John; Joseph, Shannon S; Schlachter, Dianne; Tan, Jeremy; Lynch, Judah; Oliver, Louisa; Perry, Richard; Ugradar, Shoaib

Thyroid dermopathy responds to teprotumumab therapy

甲状腺皮肤病对替普鲁单抗治疗有反应

Crespo-Trevino, Ricaurte; Schiffman, Jade; Ugradar, Shoaib; Cockerham, Kimberly; Douglas, Raymond; de Leon-Garza, David; Tang, Rosa

Commentary on: The Zoom Boom: How Video Calling Impacts Attitudes Towards Aesthetic Surgery in the COVID-19 Era

评论文章:《Zoom热潮:新冠疫情时代视频通话如何影响人们对整形手术的态度》

Ugradar, Shoaib; Massry, Guy G

Increased incidence of chalazion associated with face mask wear during the COVID-19 pandemic

新冠疫情期间佩戴口罩与霰粒肿发病率增加有关

Silkiss, Rona Z; Paap, Michael K; Ugradar, Shoaib

Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression

Teprotumumab 治疗非炎症性甲状腺眼病 (TED):IGF-1R 表达增加的证据

Shoaib Ugradar, Lu Shi, Yao Wang, Tunde Mester, Huasheng Yang, Raymond S Douglas